Quick Facts

• Primary Use: Symptomatic management of cough.
• Efficacy in: Relief of acute and chronic dry cough.
• Mechanism: Acts as a cough suppressant on the central cough reflex.

---

Cloperastine is a medication used for the symptomatic relief of cough, primarily categorized as an antitussive agent. Its main therapeutic application is to suppress the cough reflex to provide relief from acute cough and chronic dry cough.

This medication is used for cough caused by respiratory diseases such as the common cold, acute bronchitis, or chronic bronchitis. The mechanism of action involves acting on the cough center in the brain to reduce the frequency and intensity of coughing episodes. Cloperastine is noted for its ability to alleviate cough without the potential for dependency associated with opioid-based cough suppressants.

Furthermore, the compound also possesses antihistaminic activity, which may contribute to its benefit in reducing airway irritability linked to coughing.

Official Eligibility Status

The use of Cloperastine is defined by specific regulatory criteria regarding age, physiological status, and pre-existing medical conditions. Eligibility information is based on official prescribing documents, which establish clear restrictions for use.

Population	Official Regulatory Status
Infants and Young Children	Contraindicated in children under two years of age.
Pregnancy and Lactation	Contraindicated. Safety for use during these periods has not been established.
Hypersensitivity/MAOI Use	Contraindicated in patients with a known allergy to Cloperastine or antihistaminic agents, and those taking Monoamine Oxidase Inhibitors (MAOIs).

---

Use Requiring Caution (Conditional Eligibility)

Regulatory documents specify that Cloperastine must be used with caution in several patient groups due to the drug's properties and potential effects. These conditions create restrictions on use:

• Older Adults (Geriatric): Use is permitted but requires special caution.
• Organ/Metabolic Status: Caution is advised for patients with severe renal or hepatic impairment. The medicine is contraindicated in those with excipient-related metabolic disorders like hereditary fructose intolerance.
• Pre-existing Conditions: Caution is required for individuals with conditions sensitive to anticholinergic effects, such as narrow-angle glaucoma, prostatic hypertrophy, urine retention, hypertension, or cardiac arrhythmia. Use also requires caution in cases of persistent chronic cough (e.g., smoker's cough or pulmonary emphysema).

The official regulatory profile for Cloperastine focuses on specific pharmacodynamic interaction risks that require mandated constraints or cautions.

Formal Prohibited Combinations

The concurrent administration of Cloperastine with Monoamine Oxidase Inhibitors (MAOIs) is explicitly classified as a contraindicated combination in product labeling. This restriction is a formal prohibition of co-use as determined by regulatory authorities.

Enhanced Sedative Effects

A primary interaction concern is the potentiation of central nervous system (CNS) depression. Co-administration with Alcohol or any medicinal product categorized as a CNS Depressant can enhance the sedative effect. This category includes drug classes such as:

• Anxiolytics, Hypnotics, Sedatives, and Tranquilizers
• Antipsychotic drugs
• Barbiturates and Narcotics
• Certain Analgesics

Other Pharmacodynamic Interactions

Due to the drug's auxiliary pharmacological activity, an interaction with other Anticholinergic Drugs may occur. Co-administration with agents like anti-Parkinson’s drugs, tricyclic antidepressants, or neuroleptic agents can result in a reciprocal increase of anticholinergic effects.

Other Interactions

Official regulatory documents do not formally specify mandatory dose adjustments or co-administration restrictions based on CYP-mediated or transporter-based pharmacokinetic interactions. Furthermore, no mandatory temporal separation rules (e.g., administering doses hours apart) are specified in the product labeling. No specific population-dependent interaction cautions are formally noted.

Central Suppression of the Cough Reflex

Cloperastine acts primarily within the Central Nervous System (CNS), engaging in a dual-mechanistic action at key molecular targets. Its core function involves binding as a ligand to the non-opioid Sigma-1 (sigma1) receptor and functioning as a blocker of G-Protein Coupled Inwardly-Rectifying Potassium (GIRK) channels in the brainstem. These interactions reduce the excitability of neurons within the central cough center that process afferent sensory input, thereby measuringly increasing the threshold required for activation of the cough reflex.

Peripheral Receptor Modulation

Secondary to its central action, Cloperastine serves as an antagonist at both the Histamine H1 receptor ( H1R) and muscarinic acetylcholine receptors (mAChR). This antagonism modulates peripheral signaling pathways. Blockade of H1R reduces receptor-mediated responses to mediators, while mAChR antagonism results in a reduction of airway secretomotor activity. This peripheral modulation limits the inputs converging on the central cough center, supporting the overall dampening of the cough drive through a multifaceted cascade.

Cloperastine is administered exclusively through the oral route in available dosage forms, which include tablets, granules, and a liquid syrup or oral suspension. The administration protocol is defined by specific dose ranges and frequency, dependent on the patient's age group.

Dosing and Frequency

The standard pattern for Cloperastine use involves multiple doses per day, typically taken as a short course not to exceed seven days without a medical review.

Population	Typical Dose per Administration	Frequency Pattern
Adults and Adolescents (>12 yrs)	10 mg to 20 mg of the hydrochloride salt, or 10 mL of Fendizoate syrup	Three times daily (e.g., every 8 hours)
Children (6 to 12 yrs)	5 mL of the syrup formulation	Three times daily
Children (2 to 6 yrs)	2.5 mL of the syrup formulation	Three times daily

The medicine is contraindicated for use in children under 2 years of age.

Administration Requirements

Standard administration includes adherence to practical steps. Doses should be measured precisely using the provided device (for liquid formulations) and are preferably administered before meals (morning, noon, and night). Additionally, the oral suspension or syrup must be shaken thoroughly before each use to ensure proper drug distribution. In the event of a missed dose, the procedure is to skip the missed dose and resume the schedule at the next designated time, without taking a double dose.

Evidence for Symptomatic Relief of Acute and Persistent Cough

Research examined its application in conditions associated with acute or disruptive episodes, particularly those involving a cough that is either acute or persistent. The existing evidence includes Randomized Controlled Trials (RCTs), which are considered a key type of study for understanding health interventions. These trials were primarily used in research exploring how symptoms change over time in the study participants.

Researchers focused on outcomes related to physical discomfort, specifically by measuring cough frequency and cough intensity. Studies also explored patient experiences related to daily functioning, such as outcomes describing episodic or acute changes in symptoms.

Comparative Studies and Outcomes Measured

Studies often explored the product in comparison to an inactive substance (placebo) to determine outcomes related to systemic or functional imbalance. Research examined how symptoms evolved in the observed populations. Trials reported data related to changes in the frequency and intensity of coughing fits across the studied groups.

Some trials reported patterns related to measured changes in the quality and duration of night rest when assessed against baseline. For instance, some research describes patterns of change in how symptoms were measured during the study period. Because many of these measurements rely on a person's subjective assessment (such as patient diaries and overall physician assessments), the evidence quality varies across studies.

Evidence in Different Patient Groups and Causes

The initial research was primarily applied in studies examining patient-reported experiences among adult outpatients dealing with conditions characterized by fluctuating or episodic manifestations resulting from respiratory tract issues.

Studies evaluated cough related to acute or chronic respiratory conditions. Some research describes observations in mixed-age populations, including data for children, typically within observational research settings. Data for certain groups remain insufficient to fully characterize the research scope in these areas, and the results apply only to the populations studied under the specific conditions of the research.

⏳ Duration of Effect and Long-Term Follow-up

Research explored short-term symptom changes to measure how quickly the intervention began to be observed after a single use (onset of effect) and how long that initial measured effect was observed in the study participants.

However, the follow-up durations were limited in many of the core studies. This means that while research contributes to understanding short-term changes in symptom patterns, the long-term effects are not fully established. There is limited information for long-term outcomes, such as how symptoms may evolve beyond the initial period of treatment assessed in the trials.

Research Gaps and Limitations

The evidence highlights what is known from the research so far and also makes clear what is still uncertain. Evidence quality varies across studies, contributing to a situation where certainty remains low regarding some aspects of its use.

Key research limitation frames include that sample sizes were small in some clinical trials and that many primary measures of change were patient-reported outcomes describing perceived discomfort, which may introduce variability into the findings. Therefore, while research contributes to the broader evidence landscape, there is a need for more research, particularly in specific subgroups and for defining the long-term outcomes that are not yet well characterized.

Common questions about Cloperastine (FAQ)

Q: Are there reports of headache or dizziness associated with taking Cloperastine?

Official product information lists dizziness (vertigo) as an Uncommon adverse reaction, meaning it may affect up to 1 in 100 people. While other neurological effects are noted, headache is not listed in the official frequency-classified side effect profile.

Q: Can taking Cloperastine cause difficulty with urination?

Regulatory documents advise caution for individuals with pre-existing conditions sensitive to certain drug properties, such as a tendency toward urine retention. The potential for this effect is addressed in the cautionary use section of the official documents.

Q: Are there warnings about using Cloperastine while driving or operating machinery?

Official warnings state that caution is required when driving or operating machinery because the medicine can cause somnolence, which means drowsiness or sedation. This effect can impact alertness and ability to perform tasks requiring focus.

Q: Is Cloperastine generally considered safe for use in patients with kidney disease?

Official guidance advises caution for patients with severe renal impairment (severe kidney disease), as well as those with severe hepatic (liver) impairment. The official documentation advises caution for patients with severe renal impairment.

Q: Is it possible for Cloperastine to cause confusion or nervousness?

Regulatory documentation lists distractibility as an uncommon effect. Furthermore, official notes indicate that older adults may exhibit greater susceptibility to certain neurological side effects, including confusion. Mental or behavioral changes, such as confusion, are noted in official documents as potential effects, especially in older adults.

Q: Are there different brand names used for Cloperastine in various countries?

Yes, Cloperastine is the name of the active substance, but it is marketed under various trade names globally. Examples include Hustazol and Seki, which are used for its formulations in different regions, including Japan and various European countries.

Q: Is Cloperastine considered an over-the-counter (OTC) medicine in all regions?

Regulatory authorities note that the classification status (prescription or over-the-counter) for medicines in this therapeutic class is not harmonized and varies across different member states. Therefore, whether Cloperastine requires a prescription depends on the country or specific region.

Q: Does Cloperastine have properties similar to a local anesthetic in the respiratory tract?

Official classifications and descriptions indicate that the compound achieves its primary effect through central action but also possesses subtle local anesthetic effects secondary to its main antitussive action. This is noted as part of its multifaceted pharmacological profile.

Q: Is Cloperastine recommended for long-term chronic cough management?

Official usage guidelines advise that the period of treatment should not exceed seven days without re-evaluation by a healthcare professional. Caution is also advised for individuals with a persistent chronic cough, which indicates it is primarily intended for short-term symptomatic relief.

Q: Is there any information on Cloperastine's effect on blood pressure?

Official documentation lists hypotension (low blood pressure) as a Very Rare adverse reaction, meaning it may affect less than 1 in 10,000 people. Official documentation lists hypotension (low blood pressure) as a Very Rare adverse reaction.

Q: Is it normal to feel a change in vision after taking Cloperastine?

Official documentation includes reports of ocular disorders as potential adverse effects. These can include accommodation disorders, which refer to difficulty focusing the eyes. This is related to the drug's mild anticholinergic properties.

Cloperastine products must be stored and handled strictly according to the conditions defined in the official regulatory labeling to ensure product stability and safety.

Item	Labeled Regulatory Requirement
Storage Temperature	Store below a specific temperature ceiling, often not above 30°C.
Protection	Must be protected from light and moisture. Liquid formulations must not be frozen.
Packaging Rules	Keep in the original container and ensure the container is tightly closed.
Child Safety	The medicine must be kept out of the sight and reach of children.
Disposal	Disposal of unused or expired product must follow local requirements and procedures.
Environmental Rule	The medicine must not be thrown away via wastewater.

The official storage profile mandates that the product is protected from heat, light, and moisture, which is achieved by maintaining the product in its original, sealed container. For disposal, the regulatory instruction is to follow pharmaceutical waste management guidelines specific to the local area, ensuring that environmental contamination is avoided and the product is secured from children.